
|Videos|July 7, 2016
The Impact of PCSK9 Inhibitors on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Advertisement
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Notifies Flu Vaccine Makers to Add Warning for Increased Febrile Seizure Risk in Young Children Day Following Vaccination
2
Unexpected Benefits, Unexpected Limits: The Changing Landscape of GLP-1 Research
3
Phase 3 MajesTEC-9 Trial Shows Survival Benefit With Teclistamab in Multiple Myeloma
4
AI-Powered Digital Twins Offer a New Window Into Tumor Metabolism in Brain Cancer
5














































































































































































































